Esperion prelim Q4 2022 US revenue $14.4-15.1M (+38-40% YoY); CLEAR Outcomes submissions planned 1H 2023

Esperion Therapeutics, Inc.

2022-FY EPS reported -$3.52 revenue$75,475,000

Preliminary Q4 2022 U.S. net product revenue $14.4M-$15.1M; full-year 2022 growth 38%-40% YoY.
Cash and investment securities ~$167M as of Dec 31, 2022; ~74.6M shares outstanding.
Plans to submit CLEAR Outcomes data to FDA and EMA in 1H 2023; expects partner milestone payments upon approvals.
Announces 12-month marketing partnership with RFK Racing to boost brand awareness among 10M+ fans.
Presenting at J.P. Morgan 41st Annual Healthcare Conference.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported fourth-quarter 2022 results: revenue $14.4 to $15.1 million.

Period: fourth-quarter 2022
Revenue: $14.4 to $15.1 million
Result: preliminary results

Exact text from the filing

Preliminary, unaudited fourth-quarter 2022 net U.S. product sales are expected to be between $14.4 to $15.1 million; FY growth between 38% and 40% year over year.

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-000738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.